XNAS · AMLX

+13.10% · +$2.83 · Vol 1.3M

Market closed · last close 4:00 PM ET · price as of 19:58:37 ET

Amylyx Pharmaceuticals, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS

$24.46

Card

Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factors

Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET · AMLX

Methodology

Sentiment absence reason unknown

AMLX

Amylyx Pharmaceuticals, Inc. Common Stock

Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET

71/100

BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

71/ 100

Veridion Score

BUY BIAS · MEDIUM confidence

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: MEDIUM · 5/6 factors with data · Mon Aug 17 · last completed session · Markets closed · resumes Tue 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is AMLX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move AMLX next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Aug 17
Score
Score moved +39
32/SELL BIAS -> 71/BUY BIAS
Veridion score historySource
Oct 12
CongressChecking access
Christopher L. Jacobs purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Amylyx Pharmaceuticals, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS

Listed since

2022

Employees

136

Country

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$21.96

Day high

$22.47

Day low

$21.28

Previous close

$21.63

52W high